Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID HAKIMIAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1972590347
CMS profile
179978
Location
NILES, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,703.59

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,592.64 107
Education $110.95 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID HAKIMIAN

NPI 1972590347 · CMS profile ID 179978

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NILES, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972590347?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972590347?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972590347?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DAVID HAKIMIAN, NPI 1972590347, CMS profile ID 179978, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1972590347?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $2,703.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mirati Therapeutics, Inc. $21.0002/02/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057992127 CMS
Regeneron Healthcare Solutions, Inc. $18.9102/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999200731 CMS
Merck Sharp & Dohme LLC $18.1101/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048277811 CMS
SERVIER PHARMACEUTICALS LLC $23.0901/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055086691 CMS
Janssen Biotech, Inc. $17.6101/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988382423 CMS
Eisai Inc. $16.9601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023306933 CMS
Incyte Corporation $20.0901/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044401126 CMS
ABBVIE INC. $17.5601/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997418907 CMS
PFIZER INC. $25.0701/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049108669 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,839.62 57
PY2020 $2,002.76 23
PY2021 $835.14 41
PY2022 $2,026.16 100
PY2023 $2,703.59 109
PY2024 $2,277.68 92
PY2025 $2,545.96 103

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $845,278.66 327
PY2024 Principal investigator $575,151.40 117
PY2023 Principal investigator $856,007.56 264
PY2022 Recipient $3,900.00 7
PY2022 Principal investigator $43,896.65 17
PY2021 Principal investigator $90,252.10 23
PY2020 Principal investigator $83,399.80 20
PY2019 Principal investigator $117,535.70 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

327 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,000.00 12/31/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS NILES
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) No dispute reported 06/30/2026 1185554428
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753874
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387755
Principal investigator 1 Daiichi Sankyo Inc. $200.00 12/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369786
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 12/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369800
Principal investigator 1 PFIZER INC. $200.00 12/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228814247
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 12/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753366
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387753
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387757
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387759
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387761
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387763
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387765
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387767
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387769
Principal investigator 1 Daiichi Sankyo Inc. $236.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387771
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387773
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387775
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387777
Principal investigator 1 Daiichi Sankyo Inc. $47.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387779
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387781
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387783
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387785
Principal investigator 1 Daiichi Sankyo Inc. $588.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387787
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387789
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 12/11/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387791
Principal investigator 1 BioNTech SE $92.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019572
Principal investigator 1 BioNTech SE $245.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019574
Principal investigator 1 BioNTech SE $92.00 12/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
BNT327-03 No dispute reported 06/30/2026 1249019578
Principal investigator 1 Amgen Inc. $34,000.00 11/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 No dispute reported 06/30/2026 1246647989
Principal investigator 1 Janssen Research & Development, LLC $17,000.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326792
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175326843
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327699
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328188
Principal investigator 1 Janssen Research & Development, LLC $3,500.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328224
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175328821
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175329752
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369734
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369736
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369742
Principal investigator 1 Daiichi Sankyo Inc. $1,999.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369748
Principal investigator 1 Daiichi Sankyo Inc. $2,808.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369750
Principal investigator 1 Daiichi Sankyo Inc. $2,159.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369752
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369754
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369758
Principal investigator 1 Daiichi Sankyo Inc. $40.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369760
Principal investigator 1 Daiichi Sankyo Inc. $40.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369762
Principal investigator 1 Daiichi Sankyo Inc. $2,808.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369766
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369768
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369770
Principal investigator 1 Daiichi Sankyo Inc. $500.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369774
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369776
Principal investigator 1 Daiichi Sankyo Inc. $2,808.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369788
Principal investigator 1 Daiichi Sankyo Inc. $40.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369790
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369794
Principal investigator 1 Daiichi Sankyo Inc. $201.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369796
Principal investigator 1 Daiichi Sankyo Inc. $40.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369798
Principal investigator 1 Daiichi Sankyo Inc. $1,874.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369802
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369804
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369808
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369812
Principal investigator 1 Daiichi Sankyo Inc. $200.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369816
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369826
Principal investigator 1 Daiichi Sankyo Inc. $40.00 11/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369830
Principal investigator 1 Janssen Research & Development, LLC $2,100.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175327362
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753112
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $425.00 11/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753932
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 11/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387355
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387745
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387747
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387749
Principal investigator 1 Daiichi Sankyo Inc. $47.00 11/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387751
Principal investigator 1 Daiichi Sankyo Inc. $368.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387705
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387709
Principal investigator 1 Daiichi Sankyo Inc. $302.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387727
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387729
Principal investigator 1 Daiichi Sankyo Inc. $90.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387731
Principal investigator 1 Daiichi Sankyo Inc. $5,310.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387733
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/30/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387735
Principal investigator 1 Daiichi Sankyo Inc. $55.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387701
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387713
Principal investigator 1 Daiichi Sankyo Inc. $555.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387719
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387723
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387737
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 10/23/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387743
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U304 No dispute reported 06/30/2026 1223369607
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369738
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369740
Principal investigator 1 Daiichi Sankyo Inc. $418.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369744
Principal investigator 1 Daiichi Sankyo Inc. $2,239.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369746
Principal investigator 1 Daiichi Sankyo Inc. $40.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369756
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369764
Principal investigator 1 Daiichi Sankyo Inc. $200.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369772
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369778
Principal investigator 1 Daiichi Sankyo Inc. $956.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369780
Principal investigator 1 Daiichi Sankyo Inc. $40.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369782
Principal investigator 1 Daiichi Sankyo Inc. $313.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369784
Principal investigator 1 Daiichi Sankyo Inc. $4,514.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369792
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369806
Principal investigator 1 Daiichi Sankyo Inc. $179.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369810
Principal investigator 1 Daiichi Sankyo Inc. $418.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369814
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369818
Principal investigator 1 Daiichi Sankyo Inc. $3,769.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369820
Principal investigator 1 Daiichi Sankyo Inc. $170.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369822
Principal investigator 1 Daiichi Sankyo Inc. $257.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369824
Principal investigator 1 Daiichi Sankyo Inc. $77.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369828
Principal investigator 1 PFIZER INC. $957.00 10/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228814277
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 10/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753048
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387699
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387703
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387707
Principal investigator 1 Daiichi Sankyo Inc. $32,708.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387711
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387715
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387717
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387721
Principal investigator 1 Daiichi Sankyo Inc. $555.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387725
Principal investigator 1 Daiichi Sankyo Inc. $47.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387739
Principal investigator 1 Daiichi Sankyo Inc. $176.00 10/09/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387741
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $88.99 09/30/2025 Non-covered Recipient Entity
Illinois Cancer Specialists
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) No dispute reported 06/30/2026 1235996753
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387689
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387691
Principal investigator 1 Daiichi Sankyo Inc. $3,304.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387693
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387695
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 09/25/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387697
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 09/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754248
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 09/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942056
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 09/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942102
Principal investigator 1 PFIZER INC. $1,125.00 09/15/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228824557
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387353
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 08/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387685
Principal investigator 1 PFIZER INC. $66.00 08/25/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228824551
Principal investigator 1 Amgen Inc. $50.01 08/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium No dispute reported 06/30/2026 1246642495
Principal investigator 1 Amgen Inc. $50.01 08/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
MyLung Consortium Study (USOR) No dispute reported 06/30/2026 1246642499
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942068
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Study Protocol 2 (MYLUNG) No dispute reported 06/30/2026 1174942093
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942125
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 08/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942141
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 08/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753548
Principal investigator 1 Daiichi Sankyo Inc. $21,071.00 08/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387687
Principal investigator 1 PFIZER INC. $2,250.00 07/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228845245
Principal investigator 1 Daiichi Sankyo Inc. $47.00 07/18/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387683
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 07/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753358
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 07/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942042
Principal investigator 1 PFIZER INC. $957.00 07/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819256
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369613
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369619
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369635
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369655
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369663
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369730
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/16/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369732
Principal investigator 1 PFIZER INC. $3,900.00 06/16/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228847305
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 06/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753224
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369617
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369625
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369629
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369657
Principal investigator 1 Daiichi Sankyo Inc. $40.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369667
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369679
Principal investigator 1 Daiichi Sankyo Inc. $200.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369706
Principal investigator 1 PFIZER INC. $1,707.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819177
Principal investigator 1 PFIZER INC. $281.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819182
Principal investigator 1 PFIZER INC. $500.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819218
Principal investigator 1 PFIZER INC. $1,913.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819225
Principal investigator 1 PFIZER INC. $56.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819273
Principal investigator 1 PFIZER INC. $2,200.00 06/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819626
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 06/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387351
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/05/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369687
Principal investigator 1 Daiichi Sankyo Inc. $0.01 06/05/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369689
Principal investigator 1 PFIZER INC. $1,125.00 05/28/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228854655
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369683
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369685
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369714
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369716
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369718
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369720
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/21/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369722
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 05/16/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753052
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369641
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369647
Principal investigator 1 Daiichi Sankyo Inc. $1,874.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369653
Principal investigator 1 Daiichi Sankyo Inc. $1,749.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369669
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369671
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369673
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369677
Principal investigator 1 Daiichi Sankyo Inc. $200.00 05/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369724
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369702
Principal investigator 1 Daiichi Sankyo Inc. $0.01 05/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369704
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,100.00 05/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185554424
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,750.00 04/30/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS NILES
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185554426
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369621
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369633
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369637
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369639
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369708
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369710
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/29/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369712
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/24/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369623
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/24/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369627
Principal investigator 1 Daiichi Sankyo Inc. $10,416.00 04/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387675
Principal investigator 1 Daiichi Sankyo Inc. $13,421.00 04/24/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387677
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754224
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $5,200.00 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754226
Principal investigator 1 Daiichi Sankyo Inc. $47.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387679
Principal investigator 1 Daiichi Sankyo Inc. $47.00 04/17/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387681
Principal investigator 1 AstraZeneca Pharmaceuticals LP $420.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PHARMACY
A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community No dispute reported 06/30/2026 1185554434
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U304 No dispute reported 06/30/2026 1223369605
Principal investigator 1 Daiichi Sankyo Inc. $200.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369609
Principal investigator 1 Daiichi Sankyo Inc. $200.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369665
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369675
Principal investigator 1 Daiichi Sankyo Inc. $956.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369681
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369691
Principal investigator 1 Daiichi Sankyo Inc. $200.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369693
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369695
Principal investigator 1 Daiichi Sankyo Inc. $1,874.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369698
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369700
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369726
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369728
Principal investigator 1 Eli Lilly and Company $349.97 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
Not supplied No dispute reported 06/30/2026 1187883426
Principal investigator 1 Janssen Scientific Affairs, LLC $16.67 04/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942080
Principal investigator 1 Janssen Scientific Affairs, LLC $150.00 04/15/2025 Non-covered Recipient Entity
Illinois Cancer Specialists-Niles
MYLUNG Consortium Part 3: Observational Study (MYLUNG) No dispute reported 06/30/2026 1174942114
Principal investigator 1 PFIZER INC. $957.00 04/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819233
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369615
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369643
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369645
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369649
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369651
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369659
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/14/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369661
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 04/10/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387349
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369611
Principal investigator 1 Daiichi Sankyo Inc. $0.01 04/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369631
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/27/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387347
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 03/21/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192140874
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369541
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369543
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369545
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369549
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369551
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369553
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369595
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/20/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387659
Principal investigator 1 Daiichi Sankyo Inc. $2,039.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369565
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369567
Principal investigator 1 Daiichi Sankyo Inc. $40.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369569
Principal investigator 1 Daiichi Sankyo Inc. $40.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369571
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369573
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 03/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369585
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,200.00 03/14/2025 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185554432
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 03/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251754190
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387645
Principal investigator 1 Daiichi Sankyo Inc. $368.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387647
Principal investigator 1 Daiichi Sankyo Inc. $885.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387651
Principal investigator 1 Daiichi Sankyo Inc. $211.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387657
Principal investigator 1 Daiichi Sankyo Inc. $478.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387665
Principal investigator 1 Daiichi Sankyo Inc. $302.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387671
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387673
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/12/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369547
Principal investigator 1 Daiichi Sankyo Inc. $1,416.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387641
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387643
Principal investigator 1 Daiichi Sankyo Inc. $368.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387649
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387653
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387655
Principal investigator 1 Daiichi Sankyo Inc. $200.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387661
Principal investigator 1 Daiichi Sankyo Inc. $47.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387663
Principal investigator 1 Daiichi Sankyo Inc. $2,242.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387667
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 03/06/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223387669
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369531
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369533
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369535
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369537
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369539
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369589
Principal investigator 1 Daiichi Sankyo Inc. $0.01 03/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369597
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369519
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/20/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369521
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369493
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 02/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369495
Principal investigator 1 Daiichi Sankyo Inc. $1,749.00 02/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369559
Principal investigator 1 Daiichi Sankyo Inc. $200.00 02/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369593
Principal investigator 1 Daiichi Sankyo Inc. $1,125.00 02/13/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U304 No dispute reported 06/30/2026 1223387181
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369513
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369515
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369517
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369523
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369525
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369527
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/10/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369529
Principal investigator 1 Mirati Therapeutics, Inc. $5,911.20 02/07/2025 Non-covered Recipient Entity
Us Oncology Res Llc
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1236530390
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369501
Principal investigator 1 Daiichi Sankyo Inc. $0.01 02/03/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369505
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/31/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753438
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 01/30/2025 Non-covered Recipient Entity
US ONCOLOGY CLINICAL DEVELOPMENT LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192145069
Principal investigator 1 Amgen Inc. $12,683.13 01/27/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 No dispute reported 06/30/2026 1246642488
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,700.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185554436
Principal investigator 1 Daiichi Sankyo Inc. $12,967.00 01/16/2025 Non-covered Recipient Entity
US Oncology Inc
DS1062-A-U303 No dispute reported 06/30/2026 1223388271
Principal investigator 1 AstraZeneca Pharmaceuticals LP $408.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PHARMACY
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185554430
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U304 No dispute reported 06/30/2026 1223369479
Principal investigator 1 Daiichi Sankyo Inc. $956.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369481
Principal investigator 1 Daiichi Sankyo Inc. $1,749.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369487
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369489
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369491
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369497
Principal investigator 1 Daiichi Sankyo Inc. $1,749.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369555
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369557
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369561
Principal investigator 1 Daiichi Sankyo Inc. $1,914.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369563
Principal investigator 1 Daiichi Sankyo Inc. $40.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369575
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369577
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369579
Principal investigator 1 Daiichi Sankyo Inc. $200.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369581
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369583
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369587
Principal investigator 1 Daiichi Sankyo Inc. $2,039.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369591
Principal investigator 1 Daiichi Sankyo Inc. $1,906.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369601
Principal investigator 1 Daiichi Sankyo Inc. $40.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369603
Principal investigator 1 PFIZER INC. $957.00 01/15/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228819268
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,000.00 01/15/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE, LLC
ALI-4201 No dispute reported 06/30/2026 1251753002
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/07/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369483
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/07/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369509
Principal investigator 1 Mirati Therapeutics, Inc. $342,119.29 01/03/2025 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236530384
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369485
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369499
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369503
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369507
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369511
Principal investigator 1 Daiichi Sankyo Inc. $0.01 01/02/2025 Non-covered Recipient Entity
ILLINOIS CANCER SPECIALISTS PC
DS1062-A-U303 No dispute reported 06/30/2026 1223369599